-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Electra Therapeutics announced the completion of an $84 million Series B financing to develop innovative therapeutics targeting signaling regulatory proteins (SIRPs)
.
According to the announcement, the funds obtained from this financing will be used to continue to advance its lead product ELA026, which is in Phase 1 clinical development, in patients with secondary hemophagocytic lymphohistiocytosis (sHLH) and other immune diseases.
clinical trials
.
It is understood that in recent years, global pharmaceutical companies have set off a wave of financing
.
In addition to overseas companies, according to incomplete statistics, in China, there were 23 IPO pharmaceutical companies on the Science and Technology Innovation Board in the first half of last year alone, with a total financing amount exceeding 18 billion yuan
.
This year, the financing wave is still continuing.
Since February, there have been news of a large number of pharmaceutical companies obtaining large financing
.
For example, a few days ago, Pure Benchmark Technology (Beijing) Co.
, Ltd.
(hereinafter referred to as "Prix Benchmark"), a company invested by Gotega, completed the B+ round of financing
.
It is reported that this B+ round of financing is another financing completed by Purui benchmark within 4 months after the B round of 150 million yuan in September last year.
) platform upgrade, including the construction of computational module (bioinformatics platform) and experimental module (multi-omics functional laboratory)
.
At the same time, it will also enable the company to provide more comprehensive translational medicine services for more pharmaceutical partners, and help pharmaceutical partners to create innovative and differentiated pipelines
.
In addition, Qinhao Pharmaceutical (Suzhou) Co.
, Ltd.
(hereinafter referred to as "Qinhao Pharmaceutical") also announced that the company has completed a series B financing of several hundred million yuan
.
This round of financing was led by Linkage Ventures, followed by Gandao Fund, Panyi Investment, Guohai Innovation Capital and other institutions.
The old shareholder, Legend Star, continued to make additional investment
.
According to the data, Qinhao Pharmaceutical is a global innovative biopharmaceutical company, focusing on the development of original anti-tumor small molecule new drugs
.
Previously, it has completed multiple rounds of financing
.
For example, in June 2021, Qinhao Pharma announced the completion of Series A financing of over 200 million yuan
.
The investment was led by Shenzhen Venture Capital, followed by Viva Bio, Yoin Medical Fund, Lenovo Star and other institutions, and the old shareholder Shengyu Investment continued to make additional investment
.
On the same day, Jiangsu Tianrui Precision Medical Technology Co.
, Ltd.
(“Tianrui Diagnosis”), a provider of medical diagnostic service solutions, also announced the completion of the B+ round of financing of 100 million yuan
.
This round of financing will be used for the research and development and application of high-performance liquid chromatography tandem mass spectrometry clinical solutions
.
Including: registration and mass production of automatic sample pretreatment instruments for clinical mass spectrometry, development and registration of clinical mass spectrometry diagnostic reagents, development and optimization of clinical mass spectrometry AI reporting system
.
.
.
.
The industry believes that behind the continuous entry of capital, it is actually a manifestation of the accelerated innovation and development of China's pharmaceutical industry
.
In the future, under the background of the continuous support of favorable policies, the continuous growth of the domestic pharmaceutical market, and the increasing acceptance of innovative therapies in China, local innovative pharmaceutical companies will continue to use financing to accelerate the development of innovative drugs, platform, enrich the R&D pipeline, expand the international market, and further promote the development of the domestic pharmaceutical and biological industry to a higher quality direction
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to the announcement, the funds obtained from this financing will be used to continue to advance its lead product ELA026, which is in Phase 1 clinical development, in patients with secondary hemophagocytic lymphohistiocytosis (sHLH) and other immune diseases.
clinical trials
.
It is understood that in recent years, global pharmaceutical companies have set off a wave of financing
.
In addition to overseas companies, according to incomplete statistics, in China, there were 23 IPO pharmaceutical companies on the Science and Technology Innovation Board in the first half of last year alone, with a total financing amount exceeding 18 billion yuan
.
This year, the financing wave is still continuing.
Since February, there have been news of a large number of pharmaceutical companies obtaining large financing
.
For example, a few days ago, Pure Benchmark Technology (Beijing) Co.
, Ltd.
(hereinafter referred to as "Prix Benchmark"), a company invested by Gotega, completed the B+ round of financing
.
It is reported that this B+ round of financing is another financing completed by Purui benchmark within 4 months after the B round of 150 million yuan in September last year.
) platform upgrade, including the construction of computational module (bioinformatics platform) and experimental module (multi-omics functional laboratory)
.
At the same time, it will also enable the company to provide more comprehensive translational medicine services for more pharmaceutical partners, and help pharmaceutical partners to create innovative and differentiated pipelines
.
In addition, Qinhao Pharmaceutical (Suzhou) Co.
, Ltd.
(hereinafter referred to as "Qinhao Pharmaceutical") also announced that the company has completed a series B financing of several hundred million yuan
.
This round of financing was led by Linkage Ventures, followed by Gandao Fund, Panyi Investment, Guohai Innovation Capital and other institutions.
The old shareholder, Legend Star, continued to make additional investment
.
According to the data, Qinhao Pharmaceutical is a global innovative biopharmaceutical company, focusing on the development of original anti-tumor small molecule new drugs
.
Previously, it has completed multiple rounds of financing
.
For example, in June 2021, Qinhao Pharma announced the completion of Series A financing of over 200 million yuan
.
The investment was led by Shenzhen Venture Capital, followed by Viva Bio, Yoin Medical Fund, Lenovo Star and other institutions, and the old shareholder Shengyu Investment continued to make additional investment
.
On the same day, Jiangsu Tianrui Precision Medical Technology Co.
, Ltd.
(“Tianrui Diagnosis”), a provider of medical diagnostic service solutions, also announced the completion of the B+ round of financing of 100 million yuan
.
This round of financing will be used for the research and development and application of high-performance liquid chromatography tandem mass spectrometry clinical solutions
.
Including: registration and mass production of automatic sample pretreatment instruments for clinical mass spectrometry, development and registration of clinical mass spectrometry diagnostic reagents, development and optimization of clinical mass spectrometry AI reporting system
.
.
.
.
The industry believes that behind the continuous entry of capital, it is actually a manifestation of the accelerated innovation and development of China's pharmaceutical industry
.
In the future, under the background of the continuous support of favorable policies, the continuous growth of the domestic pharmaceutical market, and the increasing acceptance of innovative therapies in China, local innovative pharmaceutical companies will continue to use financing to accelerate the development of innovative drugs, platform, enrich the R&D pipeline, expand the international market, and further promote the development of the domestic pharmaceutical and biological industry to a higher quality direction
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
